Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003775 · ClinicalTrials.gov registry record · Phase 2
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00003775: Completed Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Pfizer.
NCT00003775 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Pfizer. The registered enrollment target is 60 participants, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003775, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic astrocytoma in first relapse.
Conditions Studied
Interventions
- DRUG leflunomide
Study Locations (20)
New York
- Cancer Center of Albany Medical Center - Albany
- Memorial Sloan-Kettering Cancer Center - New York
- New York Neurological Institute - New York
- Albert Einstein Comprehensive Cancer Center - The Bronx
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Henry Ford Hospital - Detroit
Ohio
- Barrett Cancer Center, The University Hospital - Cincinnati
- Arthur G. James Cancer Hospital - Ohio State University - Columbus
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
Colorado
- University of Colorado Cancer Center - Denver
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1998-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00003775 record still lists
NCT00003775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which leflunomide is the first listed.
NCT00003775 names 20 study sites across 15 states, led by New York, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT00003775 about?
NCT00003775 is a clinical study titled "Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic astrocytoma in first relapse.
What is the current status of trial NCT00003775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 1998-12. Estimated completion is 2006-05.
What conditions does trial NCT00003775 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00003775?
The interventions under investigation include: leflunomide (DRUG).
Who is sponsoring clinical trial NCT00003775?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003775 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003775's enrollment target sits among peer trials
60 19th of 45 higher than 26 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
COMPLETED · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia